Discover a new way to find and share stories you'll love… Learn about Reading Desk

All Blogs / Industries / Medical / Pharmaceutical / Popular


Ben Goldacre: Pharma industry has destroyed its own reputation

Ben Goldacre [Scott Hurst/Flickr] EXCLUSIVE: The great tragedy for the pharmaceutical industry is that it keeps denying that it lobbies against transparency in clinical trials, says Ben Goldacre. Ben Goldacre is a British physician, academic and author of the best-selling books Bad Science and Bad Pharma. Show More Summary

Patient Engagement: Who's the Engager & Who's the Engagee? #Pharma or Patient?

"There is a subtle form of power-politics implied in just about every deployment of 'patient engagement' you're likely to encounter that can serve to deprive the patient of authority rather than promote the autonomy of the patient,"Show More Summary

Weekly Roundup – 10.24.14

Autumn is well upon us.  Nature is showing us how diverse her color palette really is and it is always important to take some time and stop and enjoy it — sometimes hard to do when the demands of world … Continue reading ?

The Boehringer Ingelheim Social Media Team Receives 5th Annual PharmaGuy Social Media Pioneer Award!

Yesterday, at Digital Pharma East Mobile Day, I officially announced the recipients of the 5th Annual PharmaGuy Social Media Pioneer Award, which recognizes a pharmaceutical executive or team who has “pioneered” in the use of socialShow More Summary

A Formula for Creating Patient-Centric Mobile Health Apps

On Mobile Day at the Digital Pharma East conference (October 21, 2014), I presented a "formula" for creating "patient-centric" mobile health (mHealth) apps. My presentation focused on what I learned from comments made by REAL patients...Show More Summary

Francis Collins Knows Why We Don't Have An Ebola Vaccine

NIH Director Francis Collins has been saying that if only the agency's budget hadn't been cut, that we would already have an Ebola vaccine. He tried this line out during recent Congressional testimony, and apparently liked it enough that he expanded on it in an article for the Huffington Post. Show More Summary

Not The Sort Of Thing You'd Work With, Given a Choice

Here's a paper that illustrates a different way of looking at the world than many medicinal chemists would have. It discusses inhibitors of SETD8, an unusual epigenetic enzyme that is the only known methyltransferase to target lysine 20 of histone H4. Show More Summary

Atmospheric Conditions

Well, I've been busy sciencing away all morning, and we're having the kind of weather outside that makes a person want to stay indoors and do chemistry: rainy, chilly, and windy. You wonder why more big chemical discoveries don't come...Show More Summary

Green Coffee Beans Will Mostly Slim Your Wallet

Very few readers of this site are likely to have a good opinion of Dr. Oz (I certainly don't). And very few readers will be surprised to hear that one of his highly-touted miracle weight loss regiments - green coffee bean extract (GCA) - has turned out to be a load of faked-up nonsense. Show More Summary

Roche Rebuilds

Roche has announced ambitious plans for new buildings at its home base in Basel: They're building a new home for John Reed and Roche's pRED research group in Basel – and the pharma giant is thinking big. Roche said today that it is committing...Show More Summary

Improving the Old-Fashioned Reaction Workup

Here's something new: working up a reaction. The authors say that they have a porous polymer that adsorbs organic compounds from aqueous reaction mixtures, allowing you to just stir and filter rather than doing a liquid/liquid extraction. Show More Summary

Phenylalanine Crystals

No matter how long you've been doing chemistry, there are still things that you come across that surprise you. Did you know that plain old L-phenylalanine has been one of the most difficult subjects ever for small-molecule crystallography? I sure didn't. Show More Summary

Oxygenated Nanobubbles. For Real?

A longtime reader sent along this article, just based on the headline. "This headline triggers instant skepticism in me", he said, and I agree. "Potential to treat Alzheimer's" is both a bold and a weaselly statement to make. The weasel...Show More Summary

Compound Properties: Starting a Renunciation

I've been thinking a lot recently about compound properties, and what we use them for. My own opinions on this subject have been changing over the years, and I'm interested to see if I have any company on this. First off, why do we measure...Show More Summary

More on "Metabolite Likeness" as a Predictor

A recent computational paper that suggested that similarity to known metabolites could help predict successful drug candidates brought in a lot of comments around here. Now the folks at Cambridge MedChem Consulting have another lookShow More Summary

Different Screening, Different Thermodynamics?

Chris Lipinski and the folks at Collaborative Drug Discovery send word of an interesting webinar that will take place this coming Wednesday (October 22nd) at 2 PM EST. It's on enthalpic and entropic trends in ligand binding, and howShow More Summary

Healthcare and the Election – Stateside Ballot Initiatives

We are days away from the mid-term elections. Don’t worry, this isn’t another piece to read about how the Senate could hang in the balance for weeks; or how one party or another might retain or take control of any … Continue reading...

Thoughts on Caremark’s No-Tobacco Preferred Pharmacy Network

On Monday, The Wall Street Journal broke the news that CVS Health’s Caremark PBM will offer a new twist on preferred pharmacy networks. Consumers will face higher co-payments at pharmacies that sell tobacco products. See Caremark to Charge Extra Co-Pay at Pharmacies Selling Cigarettes. Show More Summary

The Electromagnetic Field Stem Cell Authors Respond

The authors of the ACS Nano paper on using electromagnetic fields to produce stem cells have responded on PubPeer. They have a good deal to say on the issues around the images in their paper (see the link), and I don't think that argument is over yet. Show More Summary

Copyright © 2011 Regator, LLC